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Background: Patients with Alzheimer’s disease (AD) frequently experience disruption of their circadian rhythms, but
whether and how circadian clock molecules are perturbed by AD remains unknown. AD is an age-related neurological
disorder and amyloid-β (Aβ) is one of major causative molecules in the pathogenesis of AD.
Results: In this study, we investigated the role of Aβ in the regulation of clock molecules and circadian rhythm using
an AD mouse model. These mice exhibited altered circadian behavior, and altered expression patterns of the circadian
clock genes, Bmal1 and Per2. Using cultured cells, we showed that Aβ induces post-translational degradation of the
circadian clock regulator CBP, as well as the transcription factor BMAL1, which forms a complex with the master
circadian transcription factor CLOCK. Aβ-induced degradation of BMAL1 and CBP correlated with the reduced binding
of transcription factors to the Per2 promoter, which in turn resulted in disruptions to PER2 protein expression and the
oscillation of Per2 mRNA levels.
Conclusions: Our results elucidate the underlying mechanisms for disrupted circadian rhythm in AD.
Keywords: Alzheimer’s disease (AD), Amyloid-beta (Aβ), BMAL1 (Aryl hydrocarbon receptor nuclear translocator-like),
CBP (Creb-binding protein), Circadian rhythmBackground
The circadian rhythm with a period of approximately
24 h is produced by an internal timekeeping mechanism
referred to as the circadian clock machinery [1,2]. In
mammals, the hypothalamic suprachiasmatic nucleus
(SCN), a master circadian regulator, controls behavioral
phenotypic rhythms and coordinates peripheral clocks
located in a variety of organs such as the liver, kidney,
and heart [3,4].
The physiological processes controlled by the circadian
clock include sleep, hormone secretion, and glucose
metabolism, which together determine daily circadian
oscillation patterns. The circadian clock system also main-
tains multiple circadian oscillators in various organs to
promote homeostatic balance and adaptability to the* Correspondence: inhee@snu.ac.kr
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unless otherwise stated.environment [5-7]. Disruption of the circadian rhythm in
people, by shift work for example, significantly increases
the risk of developing cardiovascular disease, cancer,
neurodegenerative disorders, and metabolic syndrome,
suggesting that circadian rhythm-controlled processes
play critical roles in human physiology and in trigger-
ing disease processes [8,9].
Alzheimer’s disease (AD) is the most common age-
dependent neurodegenerative disease. Aβ has been im-
plicated as a key mediator of AD pathology, the levels of
which are closely related with the neurodegeneration,
memory deficits and neuronal cell loss [10]. Circadian
rhythm disturbances are commonly reported in AD
patients. More than 80% of AD patients over 65 years
old suffer from circadian rhythm disorders, such as dis-
turbances in thermoregulation and sleep-wake cycles
[11,12]. Circadian disturbances become more severe as
AD severity increases [12,13]. Since circadian disturb-
ance is often noted early in the onset of AD in people, ithis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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developing AD pathology [13]; however, the underlying
mechanisms linking Aβ with circadian rhythm disrup-
tion have not yet been elucidated.
In this study, we found that circadian behaviors such
as home cage activity and body temperature were dis-
rupted in 5XFAD mice modeling AD. The current ob-
servations have extended to previous studies using AD
mouse models [14,15] and led us to hypothesize that Aβ is
a major factor underlying circadian rhythm disruptions in
5XFAD mice. Furthermore, 5XFAD mice have consist-
ently exhibited alterations to the oscillation patterns of
circadian clock genes, such as the aryl hydrocarbon recep-
tor nuclear translocator-like (Bmal1) and period circadian
protein homolog 2 (Per2). These effects on circadian
rhythm are correlated with the accelerated degradation of
BMAL1 and Creb-binding protein (CBP) in 5XFAD mice
as well as in HT22 cells. Importantly, we found that Aβ-
induced BMAL1 degradation was mediated by the sumoy-
lation of BMAL1, and that Aβ-induced CBP degradation
was mediated by N-Cadherin cleavage products. Finally,
the degradation of BMAL1 and CBP protein induced
circadian rhythm disruption by dysregulating PER2 ex-
pression. These results demonstrate a critical role for Aβ
in the disruption of the circadian clock in AD patients,
and reveal a previously unknown link between Aβ and the
degradation of BMAL1 and CBP.
Results
Abnormal circadian behavior in 5XFAD mice
Since previous studies have reported that circadian
rhythms are disrupted in AD patients as well as in AD
mouse models [14-17], we conducted behavioral assays
to determine whether the circadian rhythms of 5XFAD
mice are impaired. Both young (two months) and old
(eight months) male mice, inserted with E-mitter probes,
were entrained for one weeks to a 12 h:12 h Light–dark
(LD) cycle with water and food available ad libitum.
Their body temperature (BT) and home cage activity
(HCA) were continuously measured at 6 min intervals,
and their representative actograms are shown in Figure 1
and Additional file 1: Figure S1. Distinct daily patterns
of BT and HCA were noticeable in young 5XFAD mice
with change of BT and HCA at CT (Circadian Time)
19 and 24 h (Figure 1A,B; Additional file 2: Table S1;
Additional file 3: Table S2; Additional file 1: Figure S1A,B).
To test whether old 5XFAD mice exhibit additive be-
havioral disruption of increased circadian time, we con-
ducted circadian behavioral assays. Old 5XFAD mice
showed dramatically disrupted daily patterns in circa-
dian behavior of both BT (CT 14, 15, 20, 21 and 29 h)
and HCA (CT 12 to 25 h) compared with old littermate
mice (Figure 1C,D; Additional file 2: Table S1; Additional
file 3: Table S2; Additional file 1: Figure S1A,B). Since theabnormal circadian behavior in 5XFAD mice did not affect
light-induced behavior, we conducted behavioral assays in
constant darkness (DD) cycle. Both young and old 5XFAD
mice also exhibited an altered BT and HCA in DD cycle
compared with their littermates (Figure 1A-D; Additional
file 2: Table S1; Additional file 3: Table S2; Additional
file 1: Figure S1A–D), and two-way ANOVA revealed
that these altered daily rhythms of BT and HCA are
the results of interactions between the genotype (differ-
ence between 5XFAD mice and littermate mice) and cir-
cadian time (Table 1). These results suggest that Aβ may
affect circadian rhythm in these mice.
The expression of molecular circadian clock genes, Bmal1,
Cbp and Per2, are impaired in 5XFAD mice
To investigate the connection between the circadian be-
havioral disturbance and circadian clock genes, expres-
sion of molecular circadian clock genes such as Bmal1,
Cbp and Per2 was examined in the SCN of 5XFAD mice
(2-month-old). We first performed qRT-PCR analysis
from mice hypothalamic samples containing the SCN.
We found that the levels of Bmal1 and Per2 mRNA in
the SCN of 5XFAD mice were significantly altered, and
showed abnormal circadian oscillations compared with
those of control littermates (Figure 2A). However, Cbp
mRNA levels were not altered between littermates and
5XFAD mice (Figure 2A). We therefore analyzed oscilla-
tions in the protein levels of endogenous circadian clock
molecules in control and in 5XFAD mice (2-month-old).
In contrast to their littermates, 5XFAD mice showed no
noticeable oscillation patterns in the levels of BMAL1,
CBP and PER2 proteins (Figure 2B,C). These results
indicate that the 5XFAD mice have impairments in the
regulation of circadian clock genes.
Aβ induces the degradation of BMAL1 and CBP
It has been shown that CBP, a well-known circadian
clock control molecule [18], is associated with the cir-
cadian transcriptional co-activator, BMAL1 [19]. To de-
termine the functional relationship between CBP and
BMAL1 in cultured cells, cellular clocks were synchro-
nized in HT22 cells using a pulse treatment with Dexa-
methasone (Dex), which synchronize the cellular clock
[20], followed by a 12, 24 h treatment with 2 μM Aβ.
We found that the levels of BMAL1 and CBP proteins in
Aβ-treated cells were significantly lower compared with
those in vehicle-treated cells at CT24 as determined
using western blot (Figure 3A,B) and immunofluores-
cence assays (Figure 3C,D). To investigate the dynamic
changes in the molecular interactions between BMAL1
and CBP in living cells under physiological conditions,
we employed the BiFC assay using an enhanced yellow
fluorescence protein, Venus, which allows the visualization
of protein interactions in living cells [21]. Cos7 cells were
Figure 1 Disrupted circadian rhythm in 5XFAD mice. (A & B) Altered rhythmic waveform of home cage activity and body temperature in
two-month-old 5XFAD mice in light–dark (LD) and dark-dark (DD) cycle. (C & D) Altered rhythmic waveform of home cage activity and body
temperature in eight-month-old 5XFAD mice in LD and DD cycle.
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Table 1 ANOVA F and p values for BT and HCA rhythms
Physiological indices Factors
Circadian time Genotype Interaction
Young LD Home cage activity F(24,576)=49.97; ****p<0.0001 F(1,576)=0.58; n.s.p=0.4526 F(24.576)=2.34; ****p<0.000l
Body temperature F(24,576)=14356; ****p<0.000l F(1,576)=0.02; n.s.p=0.8802 F(24,576)=311; ****p<0.0001
Young DD Home cage activity F(23,276)=l3.77; ****p<0.0001 F(1,275)=32.60: ****p<0.0001 F(23,276)=l.57; n.s.p=0051
Body temperature F(24,288)=47.07; ****p<0.0001 F(1,288).67.53; ****p<0.0001 F(24,288)=3.42; ****p<0.0001
Old LD Home cage activity F(24.528)=101.23; ****p<0.000 F(1.528)=1818.65; ****p<0.000l F(24.528)=30.03; ****p<0.0001
Body temperature F(24.528=143.35; ****p<0.0001 F(1,528)=40.62; ****p<0.0001 F(24.528)4.34; ****p<0.0001
Old DD Home cage activity F(24.288)=14.88; ****p<0.0001 F(1.288)=13.82; **p=0.00029 F(24.288)=4.56; ****p<0.0001
Body temperature F(24.288)=57.73; ****p<0.0001 F(l,288)=133.24; ****p<0.0001 F(24.288)=6.02; ****p<0.0001
Significant differences (**p,0.01, ****p<0.0001, n.s.=not significant) are indicated in bold type.
ANOVA, analysis of variance.
Figure 2 Altered clock molecule expression in the SCN of 5XFAD mice. (A) Temporal changes in mRNA levels of clock genes in the SCN of
5XFAD mice. The total RNA of the SCN was prepared at 4 h intervals. The mRNA levels of Bmal1, Cbp and Per2 were quantified using real-time
PCR. Data are represented as mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001. (B) Temporal changes in the protein levels of clock proteins in the SCN
of 5XFAD mice. Brain samples were prepared at 4 h intervals. Western blot analysis revealed that BMAL1, CBP and PER2 protein oscillations were
decreased in 5XFAD mice. (C) Densitometric analysis of BMAL1, CBP and PER2 protein expression from three independent experiments. BMAL1,
CBP and PER2 were normalized to α-Tubulin. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01.
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Figure 3 (See legend on next page.)
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Figure 3 Aβ induced BMAL1 and CBP protein degradation in the nucleus of HT22 cells. (A-D) Aβ-induced BMAL1 and CBP protein degradation
was measured in the nucleus of HT22 cells. (A) HT22 cells were incubated with vehicle or Aβ (2 μM) for CT12, 24 after cell synchronization. Western
blot analysis showed that BMAL1 and CBP protein expression was decreased in the nucleus at CT24. (B) Densitometric analysis of BMAL1 and CBP
protein expression from three independent experiments. The intensities of the bands from BMAL1 and CBP proteins were normalized to Lamin B.
Data are represented as mean ± SEM. **P < 0.01, #P < 0.05. (C) Photomicrograph of immunostaining with BMAL1 and CBP proteins in HT22 cells clearly
shows that BMAL1 and CBP immunofluorescence are significantly decreased within the nucleus following treatment with 2 μM of Aβ for 24 h. (D)
Densitometric analysis of BMAL1 and CBP immunofluorescence from three independent experiments. Data are represented as mean ± SEM. **P < 0.01,
***P < 0.001. (E) Aβ inhibited the formation of BMAL1-CBP BiFC complexes. Cos7 cells were transiently transfected with VC-BMAL1 and VN-CBP. 12 h
post-transfection with VN-CBP and VC-BMAL1, cells were serum starved for 12 h and incubated with vehicle or Aβ for 24 h after cell synchronization.
(F) Densitometric analysis of BMAL1-CBP BiFC complexes from three independent experiments. Data are represented as mean ± SEM. ***P < 0.001.
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VN (N-terminal)-CBP. At 12 h post-transfection with
VN–CBP and VC–BMAL1, respectively, the two groups
of cells were serum-starved for 12 h, followed by syn-
chronization and incubated with vehicle or Aβ for 24 h.
We found that Aβ-induced degradation of BMAL1 and
CBP correlates with disruption of the interactions between
VC-BMAL1 and VN-CBP (Figure 3E,F). These results
were also confirmed using BMAL1-CBP immunoprecipi-
tation (Additional file 4: Figure S2). Real-time PCR ana-
lysis of the two groups showed no significant difference in
the transcription of Bmal1 and Cbp mRNAs in HT22 cells
(Additional file 5: Figure S3A,B). These results collectively
suggest that Aβ impacts on the metabolic stabilities of
BMAL1 and CBP proteins.
The degradation of BMAL1 by Aβ involves the sumoylation
of BMAL1
Sumoylation is a post-translational modification implicated
in diverse cellular systems, such as apoptosis, protein
stability, transcriptional regulation, and nuclear-cytosolic
transport [22]. It has been reported that sumoylation con-
trols the molecular clock and the stability of BMAL1 [23].
To determine whether the stability of BMAL1 is regulated
by Aβ, we monitored the degradation rate of BMAL1 in
HT22 cells using the cycloheximide (CHX) chase assay.
HT22 cells expressing GFP-BMAL1 were treated with
CHX, followed by time-course immunoblotting (at 1, 3,
and 5 h). GFP-BMAL1 was more rapidly degraded in
Aβ-treated cells compared with vehicle-treated cells
(Figure 4A,B). We further examined whether sumoy-
lation of BMAL1 is influenced by Aβ treatment. Im-
munoprecipitation assays revealed that Aβ further
induced sumoylation of BMAL1 compared with vehicle-
treated cells (Figure 4C). To examine the role of Aβ in
BMAL1 sumoylation in vivo, we used hippocampus in
5XFAD mice. Immunoprecipitation with BMAL1 specific
antibody followed by immunoblotting with SUMO1 spe-
cific antibody showed that 5XFAD mice increased the
sumoylation of BMAL1 compared with littermate mice
(Figure 4D). We hypothesized that the absence of SUMO1
might reduce the Aβ-induced degradation of BMAL1in HT22 cells. We silenced Sumo1 function using Sumo1
siRNA and measured the level of BMAL1 in Aβ-treated
cells. In Sumo1 siRNA-transfected HT22 cells, BMAL1
degradation was significantly diminished compared with
control siRNA-transfected HT22 cells (Figure 4E,F). It
is reported that BMAL1 is sumoylated on a lysine 259
(Lys259) residue [23,24]. To determine whether Aβ-induced
degradation of BMAL1 could be affected by sumoylation,
we transiently expressed wild-type BMAL1 (BMAL1
WT) or sumoylation-deficient BMAL1 (BMAL1 K259R)
in HT22 cells. Sumoylation of BMAL1 was defected in a
BMAL1 K259R mutant cDNA (Additional file 6: Figure
S4A,B). We observed that Aβ-induced degradation of
BMAL1 is mitigated by SUMO K259R mutant transfected
HT22 cells (Figure 4G,H). Collectively, these data demon-
strate that Aβ-induced BMAL1 degradation is due to the
sumoylation of BMAL1.
Aβ induces N-Cadherin CTF2-mediated degradation of
CBP through the cleavage of N-Cadherin by γ-secretase
It has been shown that the BMAL1-CLOCK-induced
circadian rhythm is stimulated by CBP recruitment to
the E-box of the Per1 promoter [19]. Another study has
shown that the N-Cadherin C-terminal fragment (CTF)
binds to CBP and induces its degradation [25]. In current
studies, N-Cadherin overexpression markedly reduced the
steady state levels of CBP (Figure 5A). Next, we deter-
mined whether Aβ would affect the generation of the
N-Cadherin CTF. We found that Aβ treatment resulted
in increased levels of N-Cadherin CTF, resulting in de-
creased levels of CBP (Figure 5B). It has been shown that
N-Cadherin is cleaved by ADAM10 to generate the N-
Cadherin CTF1, which, in turn, is cleaved by γ-secretase
to generate the N-Cadherin CTF2 [25]. To confirm the
role of γ-secretase in the cleavage of N-Cadherin, we
treated HT22 cells with the γ-secretase inhibitor L-
685,458. We found that γ-secretase-mediated cleavage of
CTF1 was significantly inhibited by L-685,458 treatment,
resulting in the accumulation of CTF1 (Figure 5C). The
reduced cleavage of CTF1 to CTF2 in L685,458-treated
cells resulted in a dose-dependent increase of CBP levels,
further suggesting that CTF2 induces CBP degradation.
Figure 4 Regulation of BMAL1 protein stability by Aβ-mediated sumoylation. (A & B) Aβ affected the stability of BMAL1 protein. HT22 cells
were incubated with CHX (100 μg/ml) with vehicle, or CHX (100 μg/ml) with Aβ (2 μM) for the indicated times. The protein level of BMAL1 was
analyzed by immunoblotting with anti-BMAL1 antibody and then quantified by densitometry. Data are represented as mean ± SEM. **P < 0.01,
***P < 0.001. (C & D) Effects of Aβ on the interaction between BMAL1 and SUMO1. (C) HT22 cells were incubated with vehicle or Aβ (2 μM) for
24 h after cell synchronization. (D) Both littermate and 5XFAD mice brains were prepared for immunoprecipitation. Each sample was immunoprecipitated
using the anti-BMAL1 antibody. Confirmation by western blot analysis with anti-SUMO-1 antibody showed that the immunoprecipitated BMAL1
was physically interacted with SUMO1. This interaction was greater with Aβ treatment. (E) The transfection of Sumo1 siRNA into HT22 cells rescued
Aβ-induced BMAL1 degradation compared to control siRNA. (F) Densitometric analysis of BMAL1 protein from three independent experiments. BMAL1
was normalized to α-Tubulin. **P < 0.01, #P < 0.05, $P < 0.05. (G) The transfection of BMAL1 K259R into HT22 cells decreased Aβ-induced BMAL1 degradation
compared to BMAL1 WT. (H) Densitometric analysis of BMAL1 protein from three independent experiments. BMAL1 was normalized to GAPDH.
***P < 0.001, #P < 0.05.
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γ-secretase activation in various systems, the current
results suggest that treatment with a γ-secretase
inhibitor might reduce Aβ-induced CBP degradation
in HT22 cells, resulting in increased levels of CBP.Western blot analysis confirmed that Aβ-induced
CBP degradation was significantly inhibited by L-685,458
treatment (Figure 5D,E). These results demonstrate that
the cleavage of N-Cadherin by γ-secretase is the molecular
mechanism underlying Aβ-induced degradation of CBP.
Figure 5 The N-Cadherin mediated degradation of CBP was induced by Aβ. (A) CBP degradation was mediated by N-Cadherin. HT22 cells
transiently transfected with the N-Cadherin construct. CBP expression was significantly decreased by N-Cadherin transfection. (B) N-Cadherin
CTF expression was increased by Aβ. HT22 cells were treated with Aβ (0 or 2 μM) for 24 h. Western blot analysis revealed that N-Cadherin CTF
expression was elevated by Aβ in a dose dependent manner. (C) γ-secretase inhibitor treatment increased CBP expression. HT22 cells were treated
with L-685,458. Western blot analysis showed that CBP expression was increased by L-685,458 in a dose dependent manner. (D) γ-secretase inhibitor
treatment rescued Aβ-induced CBP degradation. HT22 cells were incubated with Aβ only, or Aβ combined with L-685,458, for 24 h. Western blot
analysis revealed that Aβ-induced CBP degradation is ameliorated by L-685,458. (E) Densitometric analysis of CBP protein from three independent
experiments. CBP was normalized to Lamin A. **P < 0.01, ##P < 0.01.
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Aβ-mediated degradation of BMAL1 and CBP
It has been shown that BMAL1 and CLOCK induce the
expressions of the Per and cryptochrome (Cry) genes,
which, in turn, inhibit the interaction between BMAL1
and CLOCK [26,27]. Having shown that Aβ induced
BMAL1 and CBP degradation, we next reasoned that Aβ
may change the expression patterns of Per or Cry. To
test this possibility, HT22 cells were treated with 2 μM
Aβ after their cellular clocks were synchronized by pre-
treatment with 0.2 μM Dex for 2 h. Total RNA from
HT22 cells was isolated at 4 h intervals to analyze the
temporal change in the level of Per2 mRNA. The result
showed that the oscillations in Per2 mRNA levels weredisrupted in Aβ-treated cells (Figure 6A). To examine
whether Aβ treatment caused reduced binding of tran-
scription factors to the Per2 promoter, thereby disrupt-
ing PER2 protein expression and the oscillations of Per2
mRNA level, we performed a Per2-promoter activity
assay. HT22 cells were transiently transfected with the
Per2 promoter-luciferase cassette expressing luciferase
from the Per2 promoter. Transfected cells were synchro-
nized, and subsequently incubated with vehicle or 2 μM
Aβ for CT12 and 24. We found that the activity of the
Per2 promoter was significantly reduced in Aβ-treated
cells at CT24 (Figure 6B). In addition, time-course im-
munoblotting analysis of synchronized cells revealed that
the expression of PER2 protein was significantly down-
Figure 6 Aβ modulated Per2 expression. (A) Temporal expression of Per2 mRNA in Aβ-treated HT22 cell. Per2 mRNA levels in Aβ-treated HT22
cells were decreased and disrupted by circadian oscillation compared to vehicle-treated HT22 cells. Total RNA of HT22 cells was prepared at 4 h
intervals. The mRNA level of Per2 was quantified by real-time PCR. Data were represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. (B)
HT22 cells were transiently transfected with Per2-luciferacse promoter construct. HT22 cells were treated with vehicle or Aβ (2 μM) for CT12, 24
after cell synchronization. Per2-promoter activity was significantly decreased by Aβ treatment. Data are represented as mean ± SEM. **P < 0.01.
(C) HT22 cells were incubated with vehicle or Aβ (2 μM) for CT12, 24 after cell synchronization. Western blot analysis revealed that PER2 protein
expression was decreased by Aβ treatment at CT24. (D) Densitometric analysis of PER protein from three independent experiments. PER2 was
normalized to GAPDH. Data were represented as mean ± SEM. *P < 0.05. (E) Photomicrograph of immunostaining with PER2 in HT22 cells shows
that PER2 immunofluorescence was significantly decreased by 2 μM of Aβ for 24 h. (F) Densitometric analysis of PER2 immunofluorescence from
three independent experiments. Data were represented as mean ± SEM. **P < 0.01. (G) HT22 cells were treated Aβ with both L685,458 and
siSumo1 for CT12, CT24 after cell synchronization. PER2 expression was significantly increased by L685,458 and siSumo1 treatment. (H) Densitometric
analysis of PER protein from three independent experiments. PER2 was normalized to GAPDH. Data are represented as mean ± SEM.
**P < 0.01, ##P < 0.01, #P < 0.05.
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sistent with these results, immunofluorescence analysis
showed that PER2 immunofluorescence in the nucleus
of HT22 cells was significantly decreased by Aβ treat-
ment (Figure 6E,F). To block sumoylation, siSumo1 wastransfected. γ-secretase inhibitor, L685,458, was treated
to block N-cadherin cleavage. In both cases, synchro-
nized HT22 ells showed less oscillation of PER2 protein
expression in CT12 and CT24 time points, which sup-
port the importance of both pathways in oscillation of
Song et al. Molecular Neurodegeneration  (2015) 10:13 Page 10 of 15clock gene (Figure 6G,H). These results indicate that Aβ
modulates the expression of Per2 mRNA through Aβ-
mediated degradation of BMAL1 and CBP.
Discussion
Although various studies have shown that circadian
rhythms are disrupted in AD patients and animal models
of AD [12,16,17,28], little is known about the mecha-
nisms by which Aβ perturbs circadian rhythm. In the
present study, we investigated the physiological func-
tions and molecular mechanisms underlying the regula-
tion of the circadian rhythm by Aβ. Our results show
that 5XFAD mice, which overexpress Aβ and have amyl-
oid deposits in their brains, have impaired circadian be-
havior associated with the altered expression of circadian
clock molecules (Figures 1 and 2). To link a phenotypic
impairment in circadian rhythm to the molecular mech-
anism of circadian clock genes, we further characterized
the role of Aβ in transcriptional regulation, protein ex-
pression, and post-translational degradation of molecular
clocks, such as BMAL1, CBP, and PER2. Our results sug-
gest that Aβ enhances the degradation of BMAL1 and
CBP (Figure 3), leading to the perturbed expression of
PER2 at both the mRNA and protein level (Figure 6).
Aβ-induced degradation of BMAL1 correlates with the
interaction of SUMO1 with BMAL1 and Aβ-induced
sumoylation of BMAL1 (Figure 4C,D). Aβ-induced cleav-
age of the N-Cadherin CTF promotes CBP degradation
(Figure 5A,B), which is counteracted by a γ-secretase in-
hibitor (Figure 5D,E). These results collectively suggest
that Aβ may be an important causative factor underlying
the impaired circadian rhythm often observed in AD. Cir-
cadian rhythm is driven by an endogenous circadian clock,
which oscillates with a period of approximately 24 h, and
is entrainable to external cues. This fundamental biolo-
gical property has been observed in a variety of organisms,
such as mammals and plants, as well as fungi and cyano-
bacteria [29-31]. Circadian rhythm controls metabolism,
hormone secretion, sleep, and cardiac function [32-34]. It
is therefore not surprising that the disruption of the circa-
dian rhythm is closely related to many diseases such as
diabetes, obesity, bipolar disorder, cancer, and neurode-
generative diseases [6,22,32,35,36]. Recent studies have
shown that circadian rhythm is perturbed in AD patients
and mouse models of AD [1,7,9,11,33].
It is well established that core clock molecules regulate
the circadian behavioral rhythm [37-39]. Since the supra-
chiasmatic nucleus (SCN), the central master clock, syn-
chronizes central and peripheral oscillators to evoke
circadian behavioral regulation, we explored whether the
behavioral alterations in 5XFAD mice are mediated by
alterations in expression of core clock molecules in the
SCN. We found that the oscillation of circadian core clock
molecules was disrupted in SCN tissue from two-month-old 5XFAD mice (Figures 1 and 2). To confirm Aβ levels
in SCN, we measured Aβ levels in the SCN region of
2 month and 4 month old 5XFAD mice using Aβ ELISA
(Additional file 7: Figure S5A). The Aβ level in SCN was
lower than both Subiculum and Frontal cortex. Also, the
Aβ level in SCN was increased in 4 month compared to
2 month old 5XFAD mice (Additional file 7: Figure S5B),
suggesting that Aβ level in SCN is associated with
circadian rhythm disruption. We also observed that in
8-month-old 5XFAD mice, the number of NeuN-positive
cells was not altered in the SCN region (Additional file 8:
Figure S6). Therefore, circadian behavior disruption in
5XFAD mice was not affected by SCN neuronal cell loss.
Previous reports have indicated that circadian behavioral
alterations in AD patients occur before the development
of severe AD pathology. Based on these studies, we
explored whether low levels of Aβ could affect oscil-
lations in circadian molecules. We tested Aβ toxicity
using MTT, Calcein-AM cell viability assays (Additional
file 9: Figure S7), and found that 5 μM of Aβ treatment
for 24 h significantly increased cell toxicity, whereas 2 μM
of Aβ treatment, which is the concentration of Aβ we
used in this study, did not induce cellular toxicity. Inter-
estingly, 2 μM of Aβ regulated the stability of BMAL1 and
CBP proteins (Figure 3). Protein sumoylation is a post-
translational modification implied in diverse cellular
processes, such as apoptosis, protein stability, tran-
scriptional regulation, and nuclear-cytosolic transport.
It is well known that sumoylation of BMAL leads to
protein destabilization [23]. We found that the sumoyla-
tion of BMAL1 reinforced Aβ-dependent destabilization
(Figure 4A and B), whereas knockdown of Sumo1 did
not induce Aβ-mediated BMAL1 degradation (Figure 4E
and F). Sumoylation is known as an important post-
translational modification during oxidative stress. The effi-
ciency of sumoylation is affected by the exposure to stress
condition, including heat shock, osmotic, and oxidative
stress that enhance sumoylation [40]. Several lines of evi-
dence showed that altered expression of SUMO enzymes
and SNPs (single nucleotide polymorphism) of SUMO-
related genes in AD patients’ brains [41]. Our previous
study showed that Aβ induced the sumoylation of oxida-
tive stress sensitive transcription factor, Sp1, to increase
the binding of Sp1 to target gene [42]. Although the exact
mechanism how Aβ induced BMAL1 sumoylation is not
known at this moment, it is possible that Aβ activates the
SUMO conjugating enzyme to add SUMO to BMAL1
through oxidative stress sensitive signaling pathway.
N-Cadherin (N-Cad) forms complexes with PS-1 [43],
a calcium dependent cell adhesion glycoprotein containing
five extracellular cadherin repeats with a highly conserved
cytoplasmic tail and a transmembrane region. Both pro-
teins are expressed in both neurons and synapses [43,44].
N-Cad is processed by γ-secretase-dependent cleavage to
Figure 7 Schematic diagram of the role of Aβ in circadian
rhythm disruption. This diagram describes the signaling cascade
between AD and circadian rhythm, focusing on the role of Aβ.
Based on our experimental data, Aβ can regulate BMAL1 and CBP
degradation under conditions of Aβ-induced damage. BMAL1
degradation is mediated by Aβ-induced BMAL1 sumoylation. CBP
degradation is mediated by Aβ-induced N-Cadherin cleavage. Thus,
Aβ-induced BMAL1 and CBP expression results in disrupted PER2
oscillation and circadian rhythm disruption.
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CTF2 (N-Cad_CTF2) that forms complexes with CBP and
promotes its proteasomal degradation, thus acting as a
dominant repressor of CBP-mediated transcription [25].
CBP is a well-established key molecule for circadian clock
gene expression, but little is known about its regulation
despite a recent study by Ramendra et al. that has shown
CBP degradation by Aβ treatment; however, since this
CBP loss was not revealed at the level of Cbp gene expres-
sion, we confirmed that Cbp gene expression was not
affected by Aβ treatment (Additional file 5: Figure S3B).
Therefore, we hypothesized that Aβ-induced CBP degrad-
ation is mediated by N-Cad CTF. As expected, Aβ-
mediated CBP degradation was prevented by the use of a
γ-secretase inhibitor (Figure 5D,E). Figure 7 shows a sche-
matic diagram, describing the role of Aβ in circadian
rhythm disruption. BMAL1 and CBP function as up-
stream core clock molecules that regulate PER2 induction,
leading to Aβ-induced circadian rhythm disruption.
Many papers have proposed that regulators of circa-
dian rhythm could be therapeutic targets in neurodegen-
erative disorders [45,46]. In Huntington’s disease (HD),
disturbed sleep is an important symptom. HD animal
models, such as the R6/2 mouse, have also shown sleep
disruption [47]. Alprazolam is used as a hypnotic drug
to attempt to normalize sleep-wake cycles. Extended
treatment with alprazolam has significantly improved
cognitive function and clock gene oscillations in R6/2
mice. A recent study by Kang et al. revealed that circa-
dian rhythm or sleep disturbance was significantly in-
creased, and an orexin receptor antagonist markedly
decreased Aβ plaque formation, in a mouse model of
AD. Thus, disruptions to the sleep-wake cycle could ex-
acerbate the progression of neurodegenerative disorders,
and restoring a normal sleep cycle could have therapeutic
potential in neurodegenerative diseases. Moreover, a re-
cent study by Xie et al. showed that sleep drives metabol-
ite clearance of waste molecules such as Aβ from the
brain. They showed that sleep is associated with an in-
crease in the volume of the interstitial space, resulting in a
remarkable increase in convective exchange of interstitial
fluid (ISF) with cerebrospinal fluid (CSF), which increased
the rate of Aβ clearance during sleep [48].
Conclusions
Our data collectively suggest that Aβ may play a critical
functional role in circadian rhythm disruption through
degradation of BMAL1 and CBP. Furthermore, this deg-
radation was mediated by Aβ-induced sumoylation of
BMAL1 and cleavage of N-Cadherin. Therefore, the pre-
vention of Aβ-induced BMAL1 and CBP degradation, or
improved Aβ clearance by restoration of the sleep-wake
cycle, could be novel therapeutic targets for AD patho-
genesis, and warrant further investigation.Methods
AD transgenic mice
5XFAD mice express five familial AD mutations (three in
human APP: K670N/M671L (Swedish) + I716V (Florida) +
V717I (London) and two in human PSEN1: M146L +
L286V), with neuronal expression driven by the Thy-1 pro-
moter [49]. These animals were purchased from Jackson
Laboratory (Bar Harbor, ME; catalog number 006554).
Treatment and maintenance of the animals were conduc-
ted in accordance with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 85–23, revised
1985) and the Animal Care and Use Guidelines of Seoul
National University, Seoul, Korea.
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The monitoring of mouse home cage activity and body
temperature was performed as previously described [50].
A G2 E-mitter probe (Mini Mitter, Bend, OR) was surgi-
cally inserted under the skin on the dorsum of the neck
[51], and home cage activity and body temperature were
continuously monitored using the Activity Monitoring
System (Mini Mitter, Bend, OR). Data were reported at
6 min intervals using the VitalViewH Data Acquisition
System. Actograms from individually monitored mice
were obtained using ActiViewH software. To generate
the daily actogram pattern for each mouse, monitoring
results displayed as an MS Excel file for the whole time
period were either averaged (in case of body temperature),
or summed (in case of home cage activity) as 1 h bins,
and the resulting 28 day profiles were pooled according to
the indicated circadian time (CT).
Cell culture and transfection
HT22 mouse hippocampal cells and Cos7 monkey kid-
ney cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM; HyClone Laboratories, Salt Lake City,
UT) supplemented with 10% fetal bovine serum (FBS;
HyClone Laboratories, Salt Lake City, UT), 100 U/mL
penicillin, and 0.1 mg/mL streptomycin (Sigma-Aldrich,
St Louis, MO) at 37°C in a 5% CO2 incubator. The con-
trol siRNA (SC-37007) and siRNA against SUMO1 (SC-
36574) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). cDNA expression vectors for pcDNA™
3.1-mouse CBP, Per2-Luc, Myc-BMAL1, VC-BMAL1
and VN-CBP constructs were generously gifted from Dr.
Kyungjin Kim (Seoul National University, Korea). Tran-
sient transfections were performed using Lipofectamine™
LTX (Invitrogen, Carlsbad, CA) for cDNA and RNAimax
for siRNA (Invitrogen, Carlsbad, CA) according to the
instructions provided by the manufacturer.
Reagents and antibodies
Aβ, Dexamethasone (Dex), MG-132, Cycloheximide
(CHX), and L-685,458 were purchased from the American
Peptide Company (Sunnyvale, CA), Sigma-Aldrich (St.
Louis, MO), and Calbiochem (La Jolla, CA). The following
antibodies were used for immunodetection: anti-BMAL1,
anti-CBP (Santa Cruz Biotechnology Inc., Santa Cruz,
CA), anti-PER2 (Alpha Diagnostic International Inc., San
Antonio, TX), anti-Sumo1 (Cell Signaling, Beverly, MA),
anti-N-Cadherin (BD Biosciences, San Jose, CA), anti-
Lamin A (Abcam, Cambridge, MA), and anti-α-Tubulin
(Sigma-Aldrich, St Louis, MO).
Western blot analysis
Vehicle or Aβ treated cells were washed twice with ice-
cold PBS, scraped and resuspended in RIPA buffer
(50 mM Tris–HCl, pH 7.4; 150 mM NaCl; 1% NonidetP-40; 0.1% SDS; 0.5% deoxycholic acid sodium salt) con-
taining a protease inhibitor cocktail (Sigma-Aldrich, St
Louis, MO) and incubated on ice for 15 min. After cen-
trifugation at 17,000 g for 15 min, the protein concentra-
tion was determined using a BCA assay kit (Pierce,
Rockford, IL). Equal amounts of protein were resolved
using Tris-glycine polyacrylamide gels. Proteins were
transferred to PVDF membranes (Millipore, Billerica,
MA), and incubated with antibodies against target
proteins. The bands were visualized using enhanced
chemiluminescence (ECL; Amersham Pharmacia Biotech,
Buckinghamshire, England) with an image analyzer (LAS-
3000; Fuji, Tokyo, Japan).
Immunocytochemistry
Immunofluorescence using the primary antibodies for
BMAL1, CBP and PER2 was performed as previously
described [52]. Briefly, vehicle- or Aβ-treated cells were
washed twice with ice-cold PBS. Following fixation (4%
paraformaldehyde for 15 min), cells were washed with
PBS, permeabilized (0.5% Triton X-100), blocked for 1 h
(PBS containing 2% horse serum, 2% goat serum, and
2% fetal bovine serum) and incubated with primary anti-
bodies overnight at 4°C, followed by incubation with
Alexa Fluor® 488- or Alexa Fluor® 594-conjugated second-
ary antibodies (1:500, Invitrogen, Carlsbad, CA) for 1 h.
After washing, cells were counterstained for 10 min with
4′-6-Diamidino-2-phenylindole (DAPI, 1:5,000; Sigma-
Aldrich, St Louis, MO). Fluorescent signals were visual-
ized using confocal microscopy (FV10vi, Olympus, Tokyo,
Japan).
Luciferase reporter gene assay
For luciferase reporter gene assays, the Per2-Luc con-
struct was transfected using Lipofectamine™ LTX and
Plus reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Approximately 24 h after trans-
fection, cells were lysed in Passive Lysis Buffer (PLB;
Promega, Madison, WI), and luciferase activity in the
cell extracts was measured using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI).
Plasmids and BiFC assay
Bimolecular fluorescence complementation (BiFC) assays
were the same as previously reported [19]. Cos7 cells were
transiently transfected with VC-BMAL1 and VN-CBP. At
12 h post-transfection with VN–CBP and VC–BMAL1,
cells were serum starved for 12 h, and incubated with ei-
ther vehicle or Aβ for 24 h following cell synchronization.
For BiFC quantitative analyses, the cells showing nuclear
signals were measured among BiFC signal-positive cells
after serum shock synchronization in the vehicle- or Aβ-
treated cells.
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Immunoprecipitation (IP) was performed as previously
described [53]. Vehicle or Aβ-treated HT22 cells were
lysed in RIPA buffer (50 mM Tris–HCl, pH 7.5; 150 mM
sodium chloride; 0.5% sodium deoxycholate; 0.1% SDS;
1% Triton X-100; 2 mM EDTA) containing protease
inhibitors (Sigma-Aldrich). Lysates were centrifuged at
17,000 g for 15 min. Equal amounts of protein were pre-
cipitated with the anti-BMAL1 antibody at 4°C overnight
on a rotator. Protein A/G agarose beads (Santa Cruz
Biotechnology) were added to each sample and incubated
at 4°C for 1 h. IPs were collected by centrifugation and
then washed four times with the same buffer. The agarose
beads were resuspended in 10 μL of 5× sample buffer and
incubated at 95°C for 10 min to release the proteins. After
a pulse spin, the supernatants were loaded on a Tris-
glycine polyacrylamide gel for western blotting.
Real-time PCR
RNA was isolated using the RNeasyR Plus Mini Kit
(Qiagen, Valencia, CA) and cDNA was generated using
the RevertAid First Strand cDNA Synthesis Kit (Fermen-
tas, Glen Burnie, MD). Real-time PCR was performed
on the cDNA samples using ABI StepOne 2.1 (Applied
Biosystems, Foster City, CA). The primers used were
described in Kohsaka et al. [32]. The following primers
were used: mouse Bmal1, forward, 5′-CCACCTCAGA
GC CATTGATACA-3′; and reverse, 5′-GAGCAGGTT
TAGTTCCACTTTGTCT-3′; mouse Per2, forward, 5′-
TGTGCGATGATGATTCGTGA-3′; and reverse, 5′-GG
TGAAGGTACGTTT GGTTTGC-3′; mouse Cbp, for-
ward, 5′-CACAGAACCAGTTTCCATCATCCAGT-3′;
and reverse, 5′-CATGTTCAGAGGGTTAGGGAGAG
CA-3′; mouse Gapdh, forward, 5′-ACAG CCGCATC
TTCTTGTGCAGTG-3′; and reverse, 5′-GGCCTTG
ACTGTGCCGTTGAATTT-3′. The Gapdh gene was
used as an endogenous control to standardize the
amount of RNA in each reaction.
Preparation of Aβ peptide
Aβ peptide (American peptide, Sunnyvale, CA, USA)
was prepared as previously described [54]. Aβ peptide
was dissolved in 1,1,1,3,3,3,-hexafluoro-2-propanol (HFIP)
(Sigma-Aldrich). HFIP solution was divided and evapo-
rated by vacuum (SpeedVac Concentrator; Savant Instru-
ments, Hyderabad, India). Aβ peptide was maintained at
deep freezer and dissolved with anhydrous dimethyl sulf-
oxide (Sigma-Aldrich).
Aβ42 ELISA
ELISA was performed as previously described [55].
ELISA was performed for quantification of Aβ42 in the
two-month-old 5XFAD mice. Brain tissue lysed in RIPA
buffer using sonicatior and ultracentrifuged at 100,000 gat 4°C for 1 hr. The pellet was resuspended in 70% for-
mic acid solution and ultracentrifuged at 100,000 g at 4°
C for 1 hr. Protein concentrations were measured using
a BCA kit (Thermo scientific). ELISA samples were run
in duplicate on Aβ42 ELISA following the protocol of
the manufacturer (IBL, Japan). OD at 450 nm were
read on a plate reader (Powerwave XS; BIO-TEK, Winoo-
ski, VT, USA).
Statistical analysis
For statistical analysis, a Student t-test or one-way
ANOVA was performed, followed by Tukey’s post-hoc
test. (*P < 0.05, **P < 0.01, ***P < 0.001 or ###P < 0.001) using
GraphPad Prism Version 4.0 (GraphPad Software, San
Diego, CA). The factor analysis between groups was using
two-way ANOVA with Bonferroni posttests (*P < 0.05,
**P < 0.01, ***P < 0.001 or ****P < 0.001).Additional files
Additional file 1: Figure S1. Disrupted circadian rhythm in 5XFAD
mice. (A-D) Representative actograms of body temperature and home
cage activity of littermate and 5XFAD mice. (A & B) Two-month-old
5XFAD mice exhibited distinct peaks in home cage activity and body
temperature at LD and DD cycle. (C & D) Eight-month-old 5XFAD mice
exhibited distinct peaks in home cage activity and body temperature at
LD and DD cycle.
Additional file 2: Table S1. Summary of HCA rythms.
Additional file 3: Table S2. Summary of BT rythms.
Additional file 4: Figure S2. The disruption of BMAL1 and CBP
interaction was mediated by Aβ. (A) The interaction of CBP with BMAL1
was decreased by Aβ in HT22 cells. HT22 cells were transfected with CBP
and BMAL1 cDNA constructs. Twenty-four hours after transfection, cells
were incubated with vehicle or Aβ for 24 h. The cells were harvested and
lysed in lysis buffer, followed by immunoprecipitation with the anti-BMAL1
antibody. The immunoprecipitated product was analyzed with anti-CBP
antibody using western blotting.
Additional file 5: Figure S3. Temporal expression of Bmal1 and CBP
mRNA levels in Aβ-treated HT22 cells. (A & B) Bmal1 and CBP mRNA levels in
Aβ-treated HT22 cells did not show circadian oscillations compared with
vehicle-treated HT22 cells. The total RNA of HT22 was prepared at 4 h intervals.
The mRNA level of Bmal1 and CBP was quantified by real-time PCR.
Additional file 6: Figure S4. Disrupted sumoylation of BMAL1 in the
BMAL1 K259R mutant overexpressing cells. (A & B) HT22 cells were transiently
transfected with BMAL1 WT or K259R cDNA construct. Twenty-four hours
after transfection, cells were harvested and lysed with lysis buffer, followed by
immunoprecipitation with anti-BMAL1 antibody. The Immunoprecipitated
product was analyzed with anti-SUMO1 antibody.
Additional file 7: Figure S5. Measuring Aβ levels in the SCN of 5XFAD
mice. (A) RIPA soluble Aβ levels of two-month-old 5XFAD mice. (B) RIPA
soluble Aβ levels of four-month-old 5XFAD mice.
Additional file 8: Figure S6. Neuronal cell density was not altered in
the SCN region of both littermate and 5XFAD mice. (A) NeuN-positive
neuronal cell staining in the SCN region of eight-month-old littermate
mice. (B) NeuN-positive neuronal cell staining in the SCN region of
eight-month-old 5XFAD mice.
Additional file 9: Figure S7. Aβ-induced cellular toxicity was measured
by MTT and Calcein-AM cell viability assays. (A & B) HT22 cells were
incubated with Aβ at various doses and times. Using the MTT and Calcein-AM
assay, treatment of 5 μM Aβ for 24 h induced cellular toxicity. Data are
represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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